NCT06087848View on ClinicalTrials.gov

A Study to Evaluate Mesenchymal Stem Cell Product StromaForte's Effect on Cardiovascular Events

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

October 7, 2023

Primary Completion Date

October 6, 2029

Study Completion Date

October 6, 2029

Conditions
Cardiovascular Diseases
Interventions
BIOLOGICAL

Human Allogeneic Bone-Marrow-Derived Mesenchymal Stromal Cell Product (StromaForte)

100 x 106 allogeneic bone marrow (BM)-derived Mesenchymal Stromal Cell (MSC) formulated in sodium chloride supplemented with human serum albumin to be given via slow intravenous infusion in approximately 30 min

Trial Locations (1)

Unknown

RECRUITING

Live Well, Nassau

All Listed Sponsors
lead

Cellcolabs Clinical LTD.

INDUSTRY